I. The Problem
Neural tube defects (NTD) is a collective term for a group of birth defects which include anencephaly, encephalocele and spina bifida. In California. the incidence of NTD is l .I per thousand live birth~. By type and incidence. NTD can be subgrouped as: 1 Anencephaly Encephalocele Spina bifida 0.5 1 !000 0.08 / 1000 0.5 I !000
Anencephal y is incompatible with life-the affected neonate succumbs within a few hours of birth. Encephalocele is rare and generally results in some degree of mental disability.
Spina bifida will affect approximately 185 newborn infants in California each year. Successful treatment exis ts for most cases of even the worst physical disability, and most of thc~e children a rc not mentally impaired . NTD. therefore. is not a lead ing cause of morbidit) and mortality for children in California: rather. it is a potentially handicapping di!:>order for which effecti ve postna tal therapy has generallv been real i7ed.
The technology now exists which e nables the detection of only eighty percent of neural tube defects during the middle of pregnane~. Thi:-. technology consis ts of sc reeni ng the serum of their mothers for a lphafetoprotein during the 16th to the 18th week of pregnancy. Alphafewprotein is the fe tal analogue of adu lt albumin, and it is u:-.ua llyelcva ted in both the maternal serum and the amniotic nuid if the deve lop ing human is affected with an NTD o r omp hal occ le. Interestingly. the rnaternal-.erum alpha-fetoprotei n ( MSAFP) is depressed in some instances ''hen the developing human has Down's syndro me.
II. Informative Digest
In 1982. Sect ion 289.7 of the Hea lth and Safety Code was amended. requiring the Department of Heal th Service::-to promulgate regulation~ govern ing the al pha-fctop ro tei n tes t kits that were soon to be approved for market ing by the FDA. The intent of the legislative mandate \\as to protect the public from unscrupu lous marketing by the private ~ec t or which could lead to inaccu rate testing and mi si nterpretati o n of test results.~ The department failed to provide regulations. and the legis lature therefore amended the FY 1983 84 Budget Act requiring emergency regu lations. It was never the intent of the legislat ure to implement a mandatory sta tewide alpha-fetoprotein sc reening program. and this fact is appro priately demonstrated by the rejection of the e mergency legislation AB 1846 (Margoli n) in 1985.
Lori Andrews . .J .D .. project director in medical law for the America n Bar Foundation. questions\\ hether !-oUCh regulations can be respon~i\ c to pub lic opini o n: "If you're going to make policies that fo rce peo ple to und ergo medical sen·ices. sho uld the decision:. be made i r~ a back room or in the legisla ture where all in terests are heard?" 1 1 e\.ert h clc~s . the regulations were drafted in a "back roo m" fashion and subseque ntly implemented. contra ry tO lcgislati,·e intent.
Ill. The Position of Professional Organizations
In 1982. responding to the call to scree n all pregnant women for NTDs. the American College of Obstetric~ and Gynecology (ACOG) -.tated: "The risks and costs appear to outweigh the advantages and rhe program should not be implcmented ." 4 Contrary to the misinformation ""hich has been promulgated. the ACOG has neve r a ltered i t~ position. The American Medical Association (AMA) stands by it~ report by the Council on Scient ific Affa irs ,.,·hich concluded: "Maternal se rum a lpha-fetoprotein screeni ng of all pregnant women shou ld not be advocated at thi s time." 5 The fo llowing discussion wi ll clarify the reasons why the ACOG and the AMA hold this position.
The Program
In Califo rnia . 370.000 women an nuall y are in prenatal care by the 16th to the 18th week ofpregnancy.6 Usingavailablestatistics 7 .x. 9 , the statewide program in California will ... vork as is shown in Tables I and 11 .
Neural Tube Defects
The problem with the NT D screening program is the lack of reliability of the serum a lpha -fetaprote in test. The test is falsely positive (tha t is. unaffected women will test as if their baby is affected) in 95 percent of the cases.1o More distressing to the DHS is the fact that the test is falsely negati ve (that is. infants with NTD who test as normal) in 22 percent of the cases. 11
With unaffected pregnancies testing falsely positive, the level of maternal anxiety for those women participa ting has increased dramatically. This has already Jed participat ing physicians to conclude tha t the "California Alpha-Fetoprotein Screening Program should be halted or abolished alloget her". 12 This veri fies the warning by U.S. Surgeon General C. Everett K oop who, prior to the implementat ion of the program.
warned: "A positive alpha-fetoprotein test can lead women to have abortions because they can have the impression that they a re carry ing a spina bifida chi ld ".IJ James N. Macri Ph . D .. director of the NTD Laboratory at the State Univers ity of New York at S t ony Brook. noted that not all false-positive results can be e liminated so that there is a risk of aborting a normal fetus . 14 Furt hermore. Leroy Walter Ph.D .. of the Ken ned y Institute's Center for Bioethics a t Georgetow n Uni versity. said that some women whose first MSA FP screen ing lest res ul ts were positive were sufficiently frightened "that they went off and sec ured an abo rtion then and there." 1 5 This creates a dilemma for all public health screening programs. A proponent of this program. Prof. J oe Leigh S i mp~on. head of the section of human genetics a t Northwestern University. even worries that " unnecessary abo rtio ns arc likely to occur ... potentially lead ing t o a loss of public confidence in genetic sc reenin g".'~ Since elevated MSAFP leve ls will lead to 6.263 amniocenteses per year in Cal ifornia (see Table 1 ). ''the demand for chromosomal studies of amn iotic nuid fibroblasts [\\ ill] be greatly increased because. for legal reasons, it [will] be haza rdous to perform amniocentesis without performing genetic studies". II> Analysis of the data in T able I reveals that 323 developing humans will be identified as having an TO. The alleged goal of the screening program i~ to detect affected infants so that appropriate life-!>a\ing surgical intervention can be d elivered immediate ly upon birt h. It is appropriate to determine the number of these affected infant s who \~· ould require this in ter venti o n.
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Referring to Secti o n I of this report, almost one-half of those infants with NTDs will have a condition compatible with life: that is, 142 will have spina bifida cystica. According to MitchellS. Golbus M.D., professor of obstetrics, gynecology and pediatrics at the University of California at San Francisco, the only malformation requiring immediate post-nata l sterile surgica l correction is uncovered meningomyelocele. 17 Eighty percent of all spina bifida cystica births consist of uncovered meningomyeloceles, and 25 percent of these will be st illborn. 1 8 Thus, only 85 infants wou ld have been live-born with an uncovered meningomyelocele. Can the cost ofscrecning justify identifying these infants, especially since effective post-natal therapy antedates the implementation of the screening program?
Omphalocele
As mentioned, omphalocele can also be detected by an elevated M SA F P . This condition is rare: its incidence is only I :6000.1 9 According to Dr. Golbus, on ly a ruptured omphalocele requires immediate post-natal sterile surgical correction;2° approximately 18.5 percent are ruptured. 21 The sensitivity of the screening program is 73 percent. 22 
Do wn's Syndrome
The overall incidence of Down's Syndrome is I :800 live births. 24 A low MSA FP suggests its presence: however. the sensitivity of the test is only 20 percent 2 >. and the test is falsely positive in over 97 percent of the women tested. 2~> False positive screening tests are obtained with even greater frequency than is the case in neural tube defect screening. Analysis of the data in Table II indicates that 92 women will be determined to be carrying infants with Down's syndrome by t he California Alpha-Fetoprotein Screening Program . There is no current surgical impe rative to identify these infants antenarally other than for the purpose of abortion.
V. Data Analysis
The stated goal oft he California Alpha-Fetoprotein Screening Program is to enhance the sun ivai chances of affected infant~. P roponents argue that this can only be done by detecting affected infanb antcnatally in order to have a surgical team present at the instant of delivery. immediately repairing the neural tube defect or ruptured omphalocele. The following analyses show that the purported goal of the program is not s ubstantiated.
Cost Analysis
The cost of the techniqal aspects of the NTD screening program itself, as determined from Table L The costs of the technical aspects of the program for a different level of utilization (or for other areas in the Un ited States where such a program might be proposed) can be estimated by:
where x =the number of women screened.
This does not include program costs. For example, it is estimated that one genetic counselor is required for every 150 individuals identified at risk Y Referring to Tables I and II , ( Levels D and I, respectively), it , can be seen that the California program would requi re up to 91 full-time genetic counselors. The program will have to rent faci lities at each of the 19 regional centers throughout t he state. l n addition. it will have tofu nd the necessary support staff. A proposed program budget is outl ined in Table   III . Assuming the unlikely event of full participation. it will cost an average of $76.29 for each woman screened. Claiming to be self-supporting, the California Alpha-Fetoprotein Screening Program proposes to charge $40 for every woman who participates. This $36.29 per woman discrepancy ($13.4 M) will have to be compensated by the state of Ca lifornia, Medi-Cal (Medicaid). and third party insurance carriers. Underuti lization of the program will increase the differential. and it is therefore not surprising that the Screen ing P rogram has already petitioned the legislature for operational funding. The FY 86/ 87 Budget Act originally authorized $7M. but this was augmented to $12M as the program was initiated. Medi-Cal is authorized to pay for the fee for participating women covered under California's Medicaid program.28
Cost :Benefit A nalysis
The stated goal of the program is .. to detect those infants who would require immediate surgery'·. The California Alpha-Fetoprotein Screening P rogram wi ll detect 91 developing humans with an uncovered meningomye locele or ruptured omphaloce lc at a total cost of $28.228.566-that is, $310,204 for each case identified. Since it has been estimated that the lifetime medical cost of care for each person with spina bifida i~ $80.0002 11 • it is obvious that the program is not justifiable on a cost: benefit analysis.
Benefit :Risk A nalysis
The human cost of this proposed program is extremely objectionable. For every 10 developing humans identified with spina bifida eystica, omphalocele or Down's syndrome. 18 who are affected will be missed and 18 normal tiiU{f./ected one.s ll'il! he killed. (268 affected ones; 469 norma l developing humans killed -see Tables I and ll ). This analysis does not even address the enormous pub lic health consequences for the 783 women undergoing late mid-trimester abortions (see below). 10 Obviously. the program is not designed to enhance the well-being of affected infants; rather, it is a program of eugenics which institut ionalizes discrimination against handicapped children.
VI. Goal A nal ysis
What is the real purpose of identifying these developing humans? Doctor Berkowitz of the Mount Sinai Medical Center in New York says that such a program exi!>t so that "a diagnosis can be made prior to the time when pregnancy can legally be terminated (sic)". -~1 The Hastings Center concludes t hat the screening program "does detect a serious condition ... but the condition cannot be arrested or t reated except by abort ing the affected fetus."' 2 Even the California Department of Health Services concurs when it states: "As the screening program is implemented it is estimated that the number of cases diagnosed at birt~ should drop by up to 80q{·."JJ Dr. George Cunningham . Chief of the Genet ic Disease Branch in the California Department of Health Services, sta tes that he expects 90 percent of women with abnormal screening to obtain abortionsJ 4 even though their children's disab ilities would not usually be severe.
There is no in utero treatment for the affected ones. The California Department of Healrh Services. in speaking of"prevention strategies", is using a euphemism to cover the destruction of t hese developing humans in wero. The program is not even an efficient population purifica tion program: it m ust be distressing to t he e ugenicists in the DH S that this Screening Program will actually miss 472affected infants. Since the cost of discovery for each case (including aneuploidy) is at least $108. 106 and since there is no in utero treatment. should notlhese funds be used to ca re for the affected infants rather than to dest roy them?
VII . Ethical Implications
The California Alpha-Fetoprotein Screening P rogram raises ethical co ncerns in at least four areas.
Participatio n by Mandate
The regulations make it mandatory for physicians to participate in this "search and destroy" program which is part of the "prevention strategy" of the Department of Health Services. It is unethical to mandate screening tests for conditions which are not treatable. It is a violation of conscience for many physicians to participate in th is program.
Participatio n by Coercion
If an expectant mother decides not to participate, she must sign this waiver: "No. I refuse to have the alpha-fetoprotein blood screening test done. I understand and accept the consequences of this decision." If she agrees to participate, she signs: "Yes. I request that blood be drawn for the a lpha-fetoprotein screening test."3 5 The bias is obvious, and its intent is to frighten the expectant mother into participation.
Discrimination
As discussed in the preceding section. t he California Alpha-Fetoprotein Screening Program institutionalizes discrimination against handicapped children .
Restriction of U tilization
The Department of Health Services has implemented regulat ions that restrict MSAFP testing to the California Alpha-Fetoprotein Screening P rogram, at a cost of $40 to every woman participating. The test could be performed in the private sector for approximately $7. Expectant mothers, the majority of whom are opposed to it, are thus being coerced to support a program which promotes abortion. '
Conclusio n
The California Alpha-Fetoprotein Screening Program must be seen for what it really is: a eugenic population control program masquerading as an advocacy program for children with disabilities. More normal unaffected children will be killed than will be the number of abnormal ones identified by this program. T he morality, motives and tactics of the proponents of this program need to be fully exposed. It is an ethical as well as a civil rights vio lation to force expectant mothers and their physicians to participate in the California Alpha-Fetoprotein Screen ing Program.
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